Since PAR2 is a major contributor to AD, pharmacologic inhibition of PAR2 has long been expected to be of high therapeutic value, but its application remains a great change due to complex mechanisms of receptor activation and signaling. This evidence concerns the gene F2RL1 and Alzheimer disease.